Welcome to ALTG

New ALTG Study ILLUMINATE:
Feasibility is open for the ILLUMINATE Study (ALTG 16/009) which is a phase 2 trial of durvalumab and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on epidermal growth factor receptor (EGFR) mutation Tyrosine Kinase Inhibitors (TKIs).

4th ALTG Preceptorship, Melbourne:
The response has been overwhelming, and we are now at full capacity. We would like to acknowledge our sponsors for this event:
Astra Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Cancer Australia, Pfizer Oncology, and Roche

For Patients

Upcoming Events

Upcoming Events
  1. 4th ALTG Preceptorship in Lung Cancer, Melbourne, VIC

    August 17 - August 18
  2. Management Advisory Committee (MAC) Meeting

    August 31 @ 3:00 pm - 5:00 pm
  3. Scientific Advisory Committee (SAC) Meeting

    August 31 @ 3:00 pm - 5:00 pm
  4. 2018 ALTG Speaking Tour – Melbourne evening

    October 2 @ 6:00 pm - 9:00 pm
  5. 2018 ALTG Speaking Tour – Brisbane evening

    October 4 @ 6:00 pm - 9:00 pm